Company intelligence / Profile preview
CEFO
Gwangmyeong, Gyeonggi-do, South Koreacefobio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CT01, a cell-based therapeutic agent targeting osteonecrosis of the femoral head, received phase 1 clinical approval in South Korea. The company has also developed advanced manufacturing capabilities for natural killer cell therapies and maintains GMP-certified facilities. Non-clinical efficacy tests have been completed for other pipeline candidates such as CF-M801.
- Therapeutic areas
- Rheumatology
- Modalities
- Cell therapyNatural killer cell therapy (including CAR-NK, NKT)Stem cell-based therapies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Kyungpook National University HospitalKorea Research Institute of Bioscience and BiotechnologyMcGill University CanadaAnimal and Plant Quarantine Agency/Korea Racing Authority
Beyond the preview
Go deeper on CEFO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEFO.